Erythromycin Ethylsuccinate For Suspension
NDC Package 71209-103-21

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Erythromycin Ethylsuccinate for suspensions is erythromycin is used to treat a wide variety of bacterial infections. This formulation utilizes a for suspension delivery system. Marketed by Cadila Pharmaceuticals Limited, this product is identified by NDC 71209-103 and is authorized under FDA application ANDA216212.

Identification & Billing

NDC Package Code
71209-103-21
Package Description
100 mL in 1 BOTTLE
Product Code
71209-103
11-Digit Billing Format
71209010321
RxNorm Crosswalk
  • RxCUI: 686400 - erythromycin ethylsuccinate 200 MG in 5 mL Oral Suspension
  • RxCUI: 686400 - erythromycin ethylsuccinate 40 MG/ML Oral Suspension
  • RxCUI: 686400 - EES 40 MG/ML Oral Suspension
  • RxCUI: 686400 - erythromycin ethylsuccinate 200 MG per 5 ML Oral Suspension
  • RxCUI: 686418 - erythromycin ethylsuccinate 400 MG in 5 mL Oral Suspension

Clinical Specifications

Proprietary Name
Erythromycin Ethylsuccinate
Non-Proprietary Name
Erythromycin Ethylsuccinate
Substance Name
Erythromycin Ethylsuccinate
Dosage Form
For Suspension - A product, usually a solid, intended for suspension prior to administration.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
ERYTHROMYCIN ETHYLSUCCINATE 400 mg/5mL
Pharmacologic Class
Usage Information
Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Regulatory & Marketing

Labeler Name
Cadila Pharmaceuticals Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA216212
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-21-2022
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71209-103-21 identifies a specific commercial package of 100 ml in 1 bottle of Erythromycin Ethylsuccinate, a human prescription drug labeled by Cadila Pharmaceuticals Limited. This for suspension is formulated for oral use and contains erythromycin ethylsuccinate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cadila Pharmaceuticals Limited on November 21, 2022. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

How is this Cadila Pharmaceuticals Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71209010321. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71209-103-21
11-Digit CMS (5-4-2)
71209-0103-21

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.